FI69063C - Foerfarande foer framstaellning av farmaceutiskt anvaendbart 1-(p-metoxibensoyl)-2-pyrrolidinon samt i detta som mellanprodukter anvaendbara 1-(p-hydroxibensoyl)-2-pyrrolidinon 4-(p-metoxibensoylamino)smoersyra och 2-pyrrolinonderivat - Google Patents
Foerfarande foer framstaellning av farmaceutiskt anvaendbart 1-(p-metoxibensoyl)-2-pyrrolidinon samt i detta som mellanprodukter anvaendbara 1-(p-hydroxibensoyl)-2-pyrrolidinon 4-(p-metoxibensoylamino)smoersyra och 2-pyrrolinonderivat Download PDFInfo
- Publication number
- FI69063C FI69063C FI790226A FI790226A FI69063C FI 69063 C FI69063 C FI 69063C FI 790226 A FI790226 A FI 790226A FI 790226 A FI790226 A FI 790226A FI 69063 C FI69063 C FI 69063C
- Authority
- FI
- Finland
- Prior art keywords
- pyrrolidinone
- methoxybenzoyl
- compound
- preparation
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 41
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 claims description 31
- 238000002360 preparation method Methods 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 19
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 claims description 17
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 12
- VBEIIBKJHVIWOQ-UHFFFAOYSA-N 1-(4-hydroxybenzoyl)pyrrolidin-2-one Chemical compound C1=CC(O)=CC=C1C(=O)N1C(=O)CCC1 VBEIIBKJHVIWOQ-UHFFFAOYSA-N 0.000 claims description 11
- DZTVZKSCFQIBMV-UHFFFAOYSA-N 4-[(4-methoxybenzoyl)amino]butanoic acid Chemical compound COC1=CC=C(C(=O)NCCCC(O)=O)C=C1 DZTVZKSCFQIBMV-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000000543 intermediate Substances 0.000 claims description 5
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- HMXQIFUGFZEJEO-UHFFFAOYSA-N 1,2-dihydropyrrol-3-one Chemical class O=C1CNC=C1 HMXQIFUGFZEJEO-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- TXONTFRBXOCPBF-UHFFFAOYSA-N (2,3,4,5,6-pentachlorophenyl) 4-methoxybenzoate Chemical compound C1=CC(OC)=CC=C1C(=O)OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl TXONTFRBXOCPBF-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 58
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- -1 p-methoxybenzoylamino Chemical group 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- 238000010992 reflux Methods 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 6
- 206010002660 Anoxia Diseases 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 241000976983 Anoxia Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000010933 acylation Effects 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 230000007953 anoxia Effects 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 229960003878 haloperidol Drugs 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000001035 methylating effect Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- MCSGSTFQTAEWJR-UHFFFAOYSA-N (5-oxo-1-trimethylsilylpyrrolidin-3-yl) acetate Chemical compound CC(=O)OC1CN([Si](C)(C)C)C(=O)C1 MCSGSTFQTAEWJR-UHFFFAOYSA-N 0.000 description 3
- DFAOHXSXOXOHDM-UHFFFAOYSA-N 1-(4-phenylmethoxybenzoyl)pyrrolidin-2-one Chemical compound C=1C=C(OCC=2C=CC=CC=2)C=CC=1C(=O)N1CCCC1=O DFAOHXSXOXOHDM-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- 230000005978 brain dysfunction Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000002084 enol ethers Chemical class 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005051 trimethylchlorosilane Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- KKACRYNIWXDYAE-UHFFFAOYSA-N (5-oxopyrrolidin-3-yl) acetate Chemical compound CC(=O)OC1CNC(=O)C1 KKACRYNIWXDYAE-UHFFFAOYSA-N 0.000 description 2
- LUBVCBITQHEVCJ-UHFFFAOYSA-N 1-trimethylsilylpyrrolidin-2-one Chemical group C[Si](C)(C)N1CCCC1=O LUBVCBITQHEVCJ-UHFFFAOYSA-N 0.000 description 2
- ICEKEZSKMGHZNT-UHFFFAOYSA-N 4-phenylmethoxybenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1OCC1=CC=CC=C1 ICEKEZSKMGHZNT-UHFFFAOYSA-N 0.000 description 2
- QLPXKYBQRVRKPC-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-pyrrole Chemical compound COC1=CCCN1 QLPXKYBQRVRKPC-UHFFFAOYSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241001310793 Podium Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 2
- 150000008046 alkali metal hydrides Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- 229910000103 lithium hydride Inorganic materials 0.000 description 2
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- DTFMFTPWXDQAPB-UHFFFAOYSA-N 1-(3,4,5-trimethoxybenzoyl)pyrrolidin-2-one Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2C(CCC2)=O)=C1 DTFMFTPWXDQAPB-UHFFFAOYSA-N 0.000 description 1
- 150000004065 2-pyrrolines Chemical class 0.000 description 1
- IOGISYQVOGVIEU-UHFFFAOYSA-N 4-hydroxypyrrolidin-2-one Chemical compound OC1CNC(=O)C1 IOGISYQVOGVIEU-UHFFFAOYSA-N 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical class COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- LBMVENFKSRWGHV-UHFFFAOYSA-N CCCCC.P.Cl.Cl.Cl Chemical compound CCCCC.P.Cl.Cl.Cl LBMVENFKSRWGHV-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000282696 Saimiri sciureus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WPUJEWVVTKLMQI-UHFFFAOYSA-N benzene;ethoxyethane Chemical compound CCOCC.C1=CC=CC=C1 WPUJEWVVTKLMQI-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 239000012022 methylating agents Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
- 229960001844 tubocurarine Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Psychiatry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH140378 | 1978-02-10 | ||
| CH140378 | 1978-02-10 | ||
| CH1198178 | 1978-11-22 | ||
| CH1198178 | 1978-11-22 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI790226A FI790226A (fi) | 1979-08-11 |
| FI69063B FI69063B (fi) | 1985-08-30 |
| FI69063C true FI69063C (fi) | 1985-12-10 |
Family
ID=25687541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI790226A FI69063C (fi) | 1978-02-10 | 1979-01-24 | Foerfarande foer framstaellning av farmaceutiskt anvaendbart 1-(p-metoxibensoyl)-2-pyrrolidinon samt i detta som mellanprodukter anvaendbara 1-(p-hydroxibensoyl)-2-pyrrolidinon 4-(p-metoxibensoylamino)smoersyra och 2-pyrrolinonderivat |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US4369139A (ru) |
| EP (2) | EP0044088B1 (ru) |
| JP (1) | JPS6059907B2 (ru) |
| AR (1) | AR220739A1 (ru) |
| AT (1) | AT374787B (ru) |
| AU (1) | AU525514B2 (ru) |
| BG (1) | BG29281A3 (ru) |
| BR (1) | BR7900684A (ru) |
| CA (1) | CA1100515A (ru) |
| CS (1) | CS226182B2 (ru) |
| CU (1) | CU21107A3 (ru) |
| DD (1) | DD141828A5 (ru) |
| DE (1) | DE2963321D1 (ru) |
| DK (1) | DK155278C (ru) |
| EG (1) | EG13873A (ru) |
| ES (2) | ES477587A1 (ru) |
| FI (1) | FI69063C (ru) |
| GR (1) | GR71464B (ru) |
| HK (1) | HK6185A (ru) |
| HU (1) | HU177644B (ru) |
| IE (1) | IE47831B1 (ru) |
| IL (1) | IL56587A0 (ru) |
| IN (1) | IN150106B (ru) |
| MC (1) | MC1257A1 (ru) |
| MY (1) | MY8500340A (ru) |
| NO (1) | NO152046C (ru) |
| NZ (1) | NZ189571A (ru) |
| OA (1) | OA06180A (ru) |
| PH (1) | PH15491A (ru) |
| PL (1) | PL115958B1 (ru) |
| PT (1) | PT69206A (ru) |
| RO (1) | RO76615A (ru) |
| SU (1) | SU931104A3 (ru) |
| YU (1) | YU41330B (ru) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8004025A (nl) * | 1979-08-09 | 1981-02-11 | Hoffmann La Roche | Pyrrolidinederivaten en werkwijze voor het bereiden daarvan alsmede geneesmiddel. |
| CH646149A5 (de) * | 1981-02-05 | 1984-11-15 | Hoffmann La Roche | Pyrrolidin-derivat. |
| US4398938A (en) * | 1982-05-20 | 1983-08-16 | Velsicol Chemical Corporation | N-Acylated lactams and their herbicidal compositions and method of use |
| DE3326724A1 (de) * | 1983-07-25 | 1985-02-07 | Boehringer Ingelheim KG, 6507 Ingelheim | In 1-stellung substituierte 4-hydroxymethyl-pyrrolidinone, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen und zwischenprodukte |
| DE3336024A1 (de) * | 1983-10-04 | 1985-04-18 | Boehringer Ingelheim KG, 6507 Ingelheim | 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel |
| DE3420193A1 (de) * | 1984-05-30 | 1985-12-05 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue substituierte pyrrolidinone, verfahren zu ihrer herstellung und arzneimittel |
| CH661174GA3 (ru) * | 1985-07-10 | 1987-07-15 | ||
| US4691853A (en) * | 1985-12-30 | 1987-09-08 | Technalytics, Inc. | Surgical stapler |
| US5300642A (en) * | 1986-04-10 | 1994-04-05 | The Du Pont Merck Pharmaceutical Company | α, α-disubstituted aromatics and heteroaromatics as cognition enhancers |
| US4760083A (en) * | 1986-04-10 | 1988-07-26 | E. I. Dupont De Nemours & Company | 3,3-disubstituted indolines |
| US5173489A (en) * | 1986-04-10 | 1992-12-22 | The Dupont Merck Pharmaceutical Co. | α,α-disubstituted aromatics and heteroaromatics as cognition enhancers |
| US4876259A (en) * | 1987-01-05 | 1989-10-24 | E. I. Du Pont De Nemours And Company | 3,3-disubstituted indolines |
| IT1215587B (it) * | 1987-06-26 | 1990-02-14 | Roussel Maestretti Spa | Derivati della 1-benzoil2-oxo 5-alcossi pirrolidina, loro procedimento di preparazione e loro impiego come sostanza medicinale. |
| US5202345A (en) * | 1987-08-19 | 1993-04-13 | Shionogi & Co., Ltd. | Carbamoylpyrrolidone derivatives and drugs for senile dementia |
| CA1305148C (en) * | 1987-08-19 | 1992-07-14 | Hiromu Matsumura | Carbamoylpyrrolidone derivatives and drugs for senile dementia |
| JP2585086B2 (ja) * | 1988-12-28 | 1997-02-26 | 大鵬薬品工業株式会社 | ジアザビシクロアルカン誘導体 |
| IT1231921B (it) * | 1989-06-12 | 1992-01-15 | Sigma Tau Ind Farmaceuti | 1-acil-2-pirrolidoni quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
| JP2803882B2 (ja) * | 1990-02-20 | 1998-09-24 | 日清製粉株式会社 | １―フエノキシカルボニル―２―ピロリジノン誘導体 |
| JP3038032B2 (ja) * | 1991-03-25 | 2000-05-08 | 日清製粉株式会社 | 血小板凝集抑制薬 |
| ATE253909T1 (de) * | 1992-07-24 | 2003-11-15 | Univ California | Arzneimittel die den durch ampa rezeptoren vermittelten synaptischen response erhöhen |
| US5852008A (en) * | 1995-01-24 | 1998-12-22 | The Regents Of The University Of California | Heteroatom substituted benzoyl derivatives that enhance synaptic response mediated by receptors |
| CA2212829A1 (en) * | 1995-02-21 | 1996-08-29 | Jiro Takeo | Glutamic acid receptor agonist |
| FR2792833B1 (fr) * | 1999-04-27 | 2002-09-06 | Hoffmann La Roche | Utilisation de l'acide n-anisoyl-gamma-aminobutyrique ou de l'acide p-anisique pour la preparation d'une composition pharmaceutique |
| US7608636B2 (en) | 2000-12-28 | 2009-10-27 | Hamilton Pharmaceuticals, Inc. | Medicines for treatment and prevention of neurogenic pain |
| US8858594B2 (en) * | 2008-12-22 | 2014-10-14 | Abbott Laboratories | Curved closure device |
| EP2604592B1 (en) | 2011-12-12 | 2014-10-08 | Zaklady Farmaceutyczne Polpharma SA | A process for the purification of aniracetam by crystallisation from aqueous solutions |
| CN109651222A (zh) * | 2018-12-21 | 2019-04-19 | 上海昊航化工有限公司 | 一种阿尼西坦的催化合成方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3697563A (en) * | 1970-06-29 | 1972-10-10 | Inst Chemioterapico Italiano S | (3,4,5-trimethoxy-benzamido)-alkanoic acids for prophylaxis and treatment of cardiac disorders |
| DE2413935A1 (de) * | 1974-03-20 | 1975-10-16 | Schering Ag | 4-(polyalkoxy-phenyl)-2-pyrrolidone |
| ES433723A1 (es) * | 1975-01-10 | 1976-11-16 | Lafarquim S A Lab | Procedimiento de obtencion de un derivado de 2-pirrolidi- nona. |
-
1978
- 1978-01-25 CU CU7835021A patent/CU21107A3/xx unknown
-
1979
- 1979-01-01 AR AR22073979D patent/AR220739A1/es active
- 1979-01-10 IN IN27/CAL/79A patent/IN150106B/en unknown
- 1979-01-11 CA CA319,509A patent/CA1100515A/en not_active Expired
- 1979-01-16 EG EG26/79A patent/EG13873A/xx active
- 1979-01-24 FI FI790226A patent/FI69063C/fi not_active IP Right Cessation
- 1979-01-25 PH PH22107A patent/PH15491A/en unknown
- 1979-02-05 AU AU43916/79A patent/AU525514B2/en not_active Expired
- 1979-02-05 BR BR7900684A patent/BR7900684A/pt unknown
- 1979-02-05 IL IL56587A patent/IL56587A0/xx not_active IP Right Cessation
- 1979-02-05 NZ NZ189571A patent/NZ189571A/en unknown
- 1979-02-07 HU HU79HO2135A patent/HU177644B/hu not_active IP Right Cessation
- 1979-02-08 BG BG042414A patent/BG29281A3/xx unknown
- 1979-02-08 OA OA56728A patent/OA06180A/xx unknown
- 1979-02-08 JP JP54012880A patent/JPS6059907B2/ja not_active Expired
- 1979-02-08 MC MC791362A patent/MC1257A1/xx unknown
- 1979-02-08 CS CS79881A patent/CS226182B2/cs unknown
- 1979-02-08 YU YU283/79A patent/YU41330B/xx unknown
- 1979-02-08 SU SU792719854A patent/SU931104A3/ru active
- 1979-02-08 RO RO7996556A patent/RO76615A/ro unknown
- 1979-02-08 GR GR58300A patent/GR71464B/el unknown
- 1979-02-09 DK DK056379A patent/DK155278C/da not_active Application Discontinuation
- 1979-02-09 NO NO790434A patent/NO152046C/no unknown
- 1979-02-09 AT AT0099579A patent/AT374787B/de not_active IP Right Cessation
- 1979-02-09 DE DE7979100379T patent/DE2963321D1/de not_active Expired
- 1979-02-09 ES ES477587A patent/ES477587A1/es not_active Expired
- 1979-02-09 EP EP81106674A patent/EP0044088B1/de not_active Expired
- 1979-02-09 PT PT7969206A patent/PT69206A/pt unknown
- 1979-02-09 DD DD79210944A patent/DD141828A5/de unknown
- 1979-02-09 EP EP79100379A patent/EP0005143B1/de not_active Expired
- 1979-02-09 IE IE246/79A patent/IE47831B1/en not_active IP Right Cessation
- 1979-02-10 PL PL1979213340A patent/PL115958B1/pl unknown
- 1979-08-31 ES ES483756A patent/ES483756A1/es not_active Expired
-
1980
- 1980-07-14 US US06/168,906 patent/US4369139A/en not_active Expired - Lifetime
-
1985
- 1985-01-24 HK HK61/85A patent/HK6185A/xx unknown
- 1985-12-30 MY MY340/85A patent/MY8500340A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI69063C (fi) | Foerfarande foer framstaellning av farmaceutiskt anvaendbart 1-(p-metoxibensoyl)-2-pyrrolidinon samt i detta som mellanprodukter anvaendbara 1-(p-hydroxibensoyl)-2-pyrrolidinon 4-(p-metoxibensoylamino)smoersyra och 2-pyrrolinonderivat | |
| US4423044A (en) | 3,4-Dihydro-5H-2,3-benzodiazepine derivatives and pharmaceutical use thereof | |
| DE69120899T2 (de) | Neue N-Benzoylprolin-Derivate, Verfahren zur Herstellung und diese enthaltende Arzneimittel | |
| EP0005689A1 (fr) | Nouveaux acides lactame-N-acétiques et leurs amides, leurs procédés de préparation et compositions thérapeutiques | |
| FR2495153A1 (fr) | Nouvelles dibenzazepines, leur preparation et leur application comme medicaments | |
| US4829079A (en) | 1-benzenesulphonyl-2-oxo-5-alkoxypyrrolidines and medical methods of use thereof | |
| US4259337A (en) | Method for using m-trifluoromethylphenyl-piperidines | |
| US4316900A (en) | Piperazinopyrrolobenzodiazepines | |
| CH634321A5 (en) | trans-5-Aryl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indoles, process for their preparation and pharmaceutical composition containing them | |
| US4927837A (en) | Derivatives of 3-piperidine carbaldehyde oxime and their use as medicaments | |
| JPH02240098A (ja) | トリヒドロキシウルセンおよびその誘導体 | |
| US3459767A (en) | Aminomethylindoles | |
| US4228179A (en) | 3-Oxo-2-azaspiro-2-(N-methyl)-acetamides | |
| FI91410B (fi) | Menetelmä terapeuttisesti aktiivisten oktahydropyrrolo-pyratsino/2,1-i/indol-2-oni-johdannaisten valmistamiseksi | |
| US4528299A (en) | 1-(2,3-Dimethyl-4-methoxyphenyl)-2-methyl-3-(1-pyrrolidinyl)-1-propanone and anti-spastic use thereof | |
| BG99253A (en) | Epi - epibatydine derivatives | |
| FI70572B (fi) | Foerfarande foer framstaellning av farmaceutiskt anvaendbara pyrrolidinderivat samt vid deras framstaellning anvaendbara foereningar | |
| US4788212A (en) | Pyrrolidin-2-one derivatives having nootropic activity | |
| EP0233800B1 (fr) | Dérivés d'imidazo[1,2-a]quinoléines, leur préparation et leur application en thérapeutique | |
| EP0001585B1 (de) | Piperazino-pyrrolobenzodiazepine, Verfahren zu ihrer Herstellung sowie pharmazeutische Präparate enthaltend diese Verbindungen | |
| US4897414A (en) | Derivatives of 1-benzensulphonyl-2-oxo-5-alkylthio pyrrolidine, and compositions containing them | |
| US4026899A (en) | Benzo and benzothiopyranoindazole N-oxides | |
| US3937830A (en) | 5-pivaloyloxy-5-(1-phenylethyl) barbituric acid, analgetic composition and method based thereon | |
| US4885307A (en) | Derivatives of 1-arylsulphonyl-1,5-dihydro-2H-pyrrol-2-one, and compositions containing them | |
| US3966939A (en) | Novel 2-substituted 6,7-benzomorphan derivatives and salts thereof in analgesic compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: F. HOFFMANN-LA ROCHE AG |